• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results

Full Year 2014 Financial Highlights

- Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014.

- Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014.

- Cash and cash equivalents was $1.7 million at December 31, 2014, an improvement as compared to December 31, 2013;

- Net income was $4.8 million; basic and diluted earnings per share was $0.33.

Fourth Quarter 2014 Financial Highlights

- Net sales in the fourth quarter of 2014 was $14.4 million as compared to $11.0 million during the same period in 2013, representing a $3.4 million, or 31.0% increase.

- Gross profit increased by $1.6 million during the quarter.

- Net income for the quarter was $2.7 million.


News provided by

Biostar Pharmaceuticals, Inc.

Apr 15, 2015, 04:30 ET

Share this article

Share this article


XIANYANG, China, April 15, 2015 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar", "we" or the "Company"), a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced its results of operations for the full year and the quarter ended December 31, 2014.

Mr. Ronghua Wang, Chairman and CEO of Biostar Pharmaceuticals, Inc. commented: "In 2014, we experienced double digit growth in both our top line and gross profit.  We believe our positive results are the fruits of labor from our loyal and experienced team at Biostar.  By hitting 16.5% growth in sales, we were able to achieve and exceed our internal sales targets. Despite certain write-offs and one off dispositions, we were able to achieve net profit margins of 7.89%.  We believe the Company has returned to normal sustainable profit margins after weathering the storm in 2012 that adversely affected our entire industry.  We do believe through market research and input from our customers, vendors, industry experts, we were able to adapt to the market by, among other things, developing and introducing several new products to the market.  We also executed on a new sales strategy which included rolling out revised incentive compensation structure for our sales team and sales channels."

"In 2015, the Company will continually re-examine its product portfolio to focus on high margin products and expand its national sales footprint.  The Company will look to grow sales for its products via e-commerce.  Of course, the Company will not remain static with its core competency the research and development of new drugs. The Company also believes that economies of scale is vital to continue to improve its bottom line; accordingly, when the right opportunity presents itself, the Company will consider acquiring competitors to ramp up its production." In closing, Chairman Wang noted: "We will make every effort to make 2015 a banner year so that we can bring superior returns to all of our stakeholders."

*The Company's Consolidated Balance Sheets, Statement of Operations, and Cash Flows can be found at the end of this press release.  Please also refer the Company's Annual Report on Form 10K filed with the U.S. Securities and Exchange Commission for further regarding the Company's results of operations and the potential risks of investing in the Company's common stock.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to sustain its sales effort going forward, its ability to retain existing and retain new customers for its products, its ability to achieve the projected sales through the efforts of the call center, to complete the contemplated clinical trials and capitalize on such opportunities, the Company's ability to recover its sales and revenue for the gel capsule segment of its business, the state of consumer confidence and market demand or the Company's products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2014, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

Investor Relations Contact

Please send questions or comments to:
Biostar Pharmaceuticals, Inc.
Investor Relations Coordinator
+86-29-3368-6638
[email protected]
http://www.biostarpharmaceuticals.com

BIOSTAR PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS




AS OF DECEMBER 31,




2014



2013









ASSETS














Current Assets







     Cash and cash equivalents


$

1,685,154



$

80,072


     Notes receivable



-




1,636,072


     Accounts receivable, net



26,962,078




17,965,082


     Inventories



673,989




830,311


     Deposits and other receivables



4,471,992




5,282,574


     Income tax recoverable



67,370




374,958


     Loan receivables



9,772,464




9,816,433


          Total Current Assets



43,633,047




35,985,502











Non-current Assets









     Deposits



8,795,218




3,926,573


     Deferred tax assets



7,065,523




2,789,175


     Property and equipment, net



8,483,113




7,728,700


     Intangible assets, net



13,270,330




17,134,494


          Total Non-Current Assets



37,614,184




31,578,942











Total Assets


$

81,247,231



$

67,564,444











LIABILITIES AND STOCKHOLDERS' EQUITY


















Current Liabilities









     Accounts and other payables


$

5,001,086



$

4,447,314


     Short-term bank loans



3,094,614




-


     Valued-added tax payable



432,885




344,191


     Warrants liability



383,295




-


          Total Current Liabilities



8,911,880




4,791,505











Commitment and contingencies


















Stockholders' Equity









Common stock, $0.001 par value, 100,000,000 shares authorized,

        15,476,113 and 12,676,113 shares issued and outstanding

        as of December 31, 2014 and 2013



15,476




12,676


     Additional paid-in capital



30,303,508




25,748,669


     Deferred stock-based compensation



-




(365,017)


     Statutory reserve



7,354,413




7,126,432


     Retained earnings



28,269,956




23,649,725


     Accumulated other comprehensive income



6,391,998




6,600,454


          Total Stockholders' Equity



72,335,351




62,772,939











Total Liabilities and Stockholders' Equity


$

81,247,231



$

67,564,444



Please refer to the accompanying notes which form an integral part of these consolidated financial statements which can be found on Form 10-K filed with U.S. Securities and Exchange Commission.

BIOSTAR PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME




FOR THE YEARS ENDED DECEMBER 31,




2014



2013











Sales


$

61,416,587



$

52,729,054


Cost of sales



31,140,225




27,046,216


     Gross profit



30,276,362




25,682,838











Operating expenses:









     Advertising expenses



8,594,303




7,562,662


     Selling expenses



9,892,447




9,012,456


     General and administrative expenses



7,718,388




6,092,139


     Recovery of doubtful accounts



-




(1,291,510)


     Research and development expenses



2,766,162




3,228,775


     Impairment loss on other receivables



-




330,004


     Impairment loss on intangible assets



990,603




240,091


     Construction in progress written off



1,627,154




-


          Total operating expenses



31,589,057




25,174,617











(Loss) Income from operations



(1,312,695)




508,221











Other income (expense)









     Interest income



1,330,329




1,344,566


     Interest expense



(154,547)




(367,493)


     Fair value adjustment on warrants



577,599




-


     Gain on disposal of intangible assets



-




1,168,451


 Additional compensation received for the disposed land use rights


1,093,878




-


     Other



67




2,281


          Total other income, net



2,847,326




2,147,805











Income before income taxes



1,534,631




2,656,026











(Income tax benefit) Provision for income tax



(3,313,581)




1,846,980











Net income


$

4,848,212



$

809,046











Other comprehensive income



(208,456)




2,071,586











Comprehensive income


$

4,639,756



$

2,880,632











Earning per share









      Basic


$

0.33



$

0.07


      Diluted


$

0.33



$

0.07











Weighted average number of common shares outstanding









      Basic



14,499,401




11,510,802


      Diluted



14,499,401




11,510,802



Please refer to the accompanying notes which form an integral part of these consolidated financial statements which can be found on Form 10-K filed with U.S. Securities and Exchange Commission.

BIOSTAR PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS




FOR THE YEARS ENDED DECEMBER 31,




2014



2013









CASH FLOWS FROM OPERATING ACTIVITIES







Net income


$

4,848,212



$

809,046


Adjustments to reconcile net income to net cash provided by operating activities:









     Deferred income tax (benefit) expense



(4,284,655)




981,390


     Depreciation and amortization



3,086,188




2,786,702


     Recovery of doubtful accounts



-




(1,291,510)


     Recognition of deferred research and development expenses



2,766,162




3,228,775


     Impairment loss on other receivables



-




330,004


     Impairment loss on intangible assets



990,603




240,091


     Construction in progress written off



1,627,154




-


     Loss on disposal of property, plant and equipment



3,275




-


     Gain on disposal of intangible assets



-




(1,168,451)


     Additional compensation received for the disposed land use rights



(1,093,878)




-


     Stock-based compensation



2,021,017




757,380


     Warrants liability



(577,599)




-


Changes in operating assets and liabilities:









     Accounts receivable and notes receivable



(7,441,446)




4,204,776


     Inventories



152,454




43,461


     Deposits and other receivables



244,270




(161,358)


     Accounts payable and accrued expenses



573,102




(1,449,439)


     Value-added tax payable



90,148




(301,662)


     Income tax payable (recoverable)



305,611




(100,092)


Net cash provided by operating activities



3,310,618




8,909,113











CASH FLOWS FROM INVESTING ACTIVITIES









Purchase of property, plant and equipment



(2,869,204)




(982,012)


Proceeds from disposal of property, plant and equipment



2,929




-


Deposit paid for research and development



(4,067,885)




(2,744,459)


Deposit paid for intended acquisitions



(4,881,462)




(3,874,530)


Proceeds from disposal of two drug approval numbers



1,390,661




-


Compensation received for disposed land use rights



1,546,822




3,390,214


Net cash used in investing activities



(8,878,139)




(4,210,787)











CASH FLOWS FROM FINANCING ACTIVITIES









Repayment to a related party



-




(1,614,387)


Proceeds from short-term bank loans



3,254,307




-


Repayment of short-term bank loans



(162,715)




(4,843,162)


Proceeds from stock issuance and warrants



3,862,533




-


Net cash provided by (used in) financing activities



6,954,125




(6,457,549)











Effect of exchange rate changes on cash and cash equivalents



218,478




80,217











Net increase (decrease) in cash and cash equivalents



1,605,082




(1,679,006)











Cash and cash equivalents, beginning balance



80,072




1,759,078


Cash and cash equivalents, ending balance


$

1,685,154



$

80,072











SUPPLEMENTAL DISCLOSURES:









Interest received


$

1,330,329



$

1,344,566


Interest paid


$

(154,547)



$

(355,657)


Income tax paid


$

(665,621)



$

(965,681)



Please refer to the accompanying notes which form an integral part of these consolidated financial statements which can be found on Form 10-K filed with U.S. Securities and Exchange Commission.

SOURCE Biostar Pharmaceuticals, Inc.

Related Links

http://www.biostarpharmaceuticals.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.